Trump Threatens 100% Tariffs on US Drug Makers Over Pricing Deals
Donald Trump is threatening to impose 100% tariffs on pharmaceutical companies that fail to strike agreements to lower drug prices in the United States. This new tax will specifically target branded drugs and their active ingredients, while generic drugs, which account for over 90% of medicines sold in the US, will be exempt from tariffs for at least one year.
Exemptions and Negotiations
Orphan, veterinary, and other specialty drugs are also exempt if they originate from countries with trade deals or meet urgent public health needs. Drugmakers that enter into pricing agreements with the White House and relocate production to the US will be spared from the tariffs. Companies planning to increase domestic manufacturing will face a 20% tariff initially, escalating to 100% over four years.
The US has already granted exemptions to 17 drugmakers, with negotiations ongoing for four of them. Major pharmaceutical firms like Pfizer and Eli Lilly have signed deals, securing tariff exemptions for three years. Large companies have a 120-day window before the tariffs take effect to negotiate with the White House, while smaller firms have 180 days.
Industry Concerns and Policy Context
The Midsized Biotech Alliance of America (MBAA) has criticized the executive order, warning it could create an unfair two-tiered system of exemptions that benefits only large companies with existing most-favored-nation agreements. MBAA president Alanna Temme stated that mid-sized drugmakers lack diversified portfolios to absorb these sudden cost increases.
Trump's move is part of his most-favored-nation drug pricing policy, aimed at pressuring companies to align US prices with those in other high-income countries. Currently, US patients pay nearly triple for prescription medicines compared to other developed nations. The announcement comes amid consumer pressure to lower prices, exacerbated by tariff-related increases and high gas prices linked to the US-Israel conflict with Iran.
In January, Trump outlined economic policies to address the rising cost of living, blaming the Biden administration. These include banning large institutional investors from purchasing single-family homes and capping credit card interest rates at 10%. Regarding drug prices, Trump previously remarked that on that alone, we should win the midterms, highlighting the political stakes of this issue.
